155 results on '"Armstrong, Paul W."'
Search Results
2. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
3. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial
4. Ameliorating reperfusion injury in STEMI: dead or alive?
5. The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions
6. Learning whether to subtract beta-blockers: it’s about time
7. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
8. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint
9. Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review
10. Third universal definition of myocardial infarction
11. Road mapping ATLAS ACS 2: are we there yet?
12. The future of clinical trials in secondary prevention after acute coronary syndromes
13. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis
14. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial
15. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
16. Towards a new order in cardiovascular medicine: re-engineering through global collaboration
17. Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction
18. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention
19. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis
20. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
21. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study
22. Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb
23. Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy
24. Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI
25. Cardiovascular disease on a global scale: defining the path forward for research and practice
26. †Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction
27. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women
28. Ruminating on OAT: is the case closed?
29. The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction
30. Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes
31. International variation in invasive care of the elderly with acute coronary syndromes
32. FASTTRACK A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study
33. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
34. Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial
35. Aborted myocardial infarction: a new target for reperfusion therapy
36. Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
37. How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts
38. Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction
39. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial
40. A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy
41. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial
42. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials
43. Assessing risk in FRISC
44. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry
45. The continuous heart failure spectrum: moving beyond an ejection fraction classification
46. Learning whether to subtract beta-blockers: it's about time.
47. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial
48. continuous heart failure spectrum: moving beyond an ejection fraction classification.
49. Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula
50. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.